{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:50Z","timestamp":1793242310245,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Se\u0301zary syndrome (SzS) is an advanced form of cutaneous T-cell lymphoma characterized by peripheral blood involvement, impaired cell-mediated immunity, and T-helper 1 (TH1) cytokine production. To understand the mechanism of these defects, we studied the expression and function of CD40L in peripheral blood mononuclear cells (PBMCs) of patients with SzS. We found that PBMCs of patients with SzS have a defect in interleukin-12 (IL-12) and tumor necrosis factor-\u03b1 (TNF-\u03b1) production upon anti-CD3 stimulation and that tumor CD4+ T lymphocytes have a specific defect in CD40L induction after anti-CD3 ligation in vitro. This defect may explain the poor IL-12 production, because IL-12 production by anti-CD3-stimulated PBMCs was dependent on CD40L in healthy donors. The observed defect in tumor cell CD40L expression appears to be due to inappropriate T-cell signaling upon CD3 ligation, because expression of other T-cell activation antigens such as CD25, and to a lesser extent CD69, are also impaired on tumor cells. Importantly however, the inability of SzS PBMCs to appropriately produce IL-12 and TNF-\u03b1 could be restored by recombinant hexameric CD40L. Taken together, our results demonstrate that impaired IL-12 and TNF-\u03b1 production in SzS is associated with defective CD4+ T lymphocyte CD40L induction and indicate that CD40L may have therapeutic potential in SzS. (Blood. 2005;105:219-225)<\/jats:p>","DOI":"10.1182\/blood-2004-03-1055","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T01:08:20Z","timestamp":1092791300000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Impaired CD40L signaling is a cause of defective IL-12 and TNF-\u03b1 production in Se\u0301zary syndrome: circumvention by hexameric soluble CD40L"],"prefix":"10.1182","volume":"105","author":[{"given":"Lars E.","family":"French","sequence":"first","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Huard","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wysocka","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shane","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Contassot","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Franc\u0327ois","family":"Arrighi","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Calderara","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"From the Louis-Jeantet Skin Cancer Laboratory, Department of Dermatology, Geneva University Medical School, Switzerland; Apotech, Epalinges, Switzerland; and Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219520746800_REF1","doi-asserted-by":"crossref","unstructured":"Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T cells. Arch Dermatol.1993;129: 486-489.","DOI":"10.1001\/archderm.1993.01680250098016"},{"key":"2020021219520746800_REF2","doi-asserted-by":"crossref","unstructured":"Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol.1995;131: 1003-1008.","DOI":"10.1001\/archderm.1995.01690210033005"},{"key":"2020021219520746800_REF3","doi-asserted-by":"crossref","unstructured":"Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol.1992;99: 90-94.","DOI":"10.1111\/1523-1747.ep12611877"},{"key":"2020021219520746800_REF4","doi-asserted-by":"crossref","unstructured":"Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol.1994;103: 669-673.","DOI":"10.1111\/1523-1747.ep12398454"},{"key":"2020021219520746800_REF5","doi-asserted-by":"crossref","unstructured":"Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood.1996;88: 1383-1389.","DOI":"10.1182\/blood.V88.4.1383.bloodjournal8841383"},{"key":"2020021219520746800_REF6","doi-asserted-by":"crossref","unstructured":"Wood NL, Kitces EN, Blaylock WK. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol.1990;126: 907-913.","DOI":"10.1001\/archderm.1990.01670310069009"},{"key":"2020021219520746800_REF7","doi-asserted-by":"crossref","unstructured":"Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol.1996;35: 946-957.","DOI":"10.1016\/S0190-9622(96)90119-X"},{"key":"2020021219520746800_REF8","doi-asserted-by":"crossref","unstructured":"Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood.1999;94: 902-908.","DOI":"10.1182\/blood.V94.3.902.415k23_902_908"},{"key":"2020021219520746800_REF9","doi-asserted-by":"crossref","unstructured":"Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol.1996;156: 3932-3938.","DOI":"10.4049\/jimmunol.156.10.3932"},{"key":"2020021219520746800_REF10","doi-asserted-by":"crossref","unstructured":"McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA. CD40 ligand\/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and\/or CD28-dependent manner. J Immunol.1998;160: 1701-1707.","DOI":"10.4049\/jimmunol.160.4.1701"},{"key":"2020021219520746800_REF11","doi-asserted-by":"crossref","unstructured":"Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med.1996;183: 693-698.","DOI":"10.1084\/jem.183.2.693"},{"key":"2020021219520746800_REF12","unstructured":"Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res.1998;58: 2965-2968."},{"key":"2020021219520746800_REF13","doi-asserted-by":"crossref","unstructured":"Ranheim EA, Kipps TJ. Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med.1993;177: 925-935.","DOI":"10.1084\/jem.177.4.925"},{"key":"2020021219520746800_REF14","doi-asserted-by":"crossref","unstructured":"Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science.1996;273: 1862-1864.","DOI":"10.1126\/science.273.5283.1862"},{"key":"2020021219520746800_REF15","doi-asserted-by":"crossref","unstructured":"Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity.1996;4: 283-289.","DOI":"10.1016\/S1074-7613(00)80436-7"},{"key":"2020021219520746800_REF16","doi-asserted-by":"crossref","unstructured":"Kamanaka M, Yu P, Yasui T, et al. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity.1996;4: 275-281.","DOI":"10.1016\/S1074-7613(00)80435-5"},{"key":"2020021219520746800_REF17","doi-asserted-by":"crossref","unstructured":"Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest.1999;103: 1151-1158.","DOI":"10.1172\/JCI5891"},{"key":"2020021219520746800_REF18","doi-asserted-by":"crossref","unstructured":"Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol.1980;2: 89-106.","DOI":"10.1016\/S0190-9622(80)80385-9"},{"key":"2020021219520746800_REF19","unstructured":"Murphy GF. Cutaneous T-cell lymphoma. Adv Pathol.1988;1: 131-156."},{"key":"2020021219520746800_REF20","doi-asserted-by":"crossref","unstructured":"Rook AH, Suchin KR, Kao DM, et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc.1999;4: 85-90.","DOI":"10.1038\/sj.jidsp.5640188"},{"key":"2020021219520746800_REF21","doi-asserted-by":"crossref","unstructured":"Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol.1995;154: 1491-1498.","DOI":"10.4049\/jimmunol.154.3.1491"},{"key":"2020021219520746800_REF22","doi-asserted-by":"crossref","unstructured":"Arrighi JF, Hauser C, Chapuis B, Zubler RH, Kindler V. Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-)CD14(-) and a CD34(-)CD14(+) dendritic cell precursor. Blood.1999;93: 2244-2252.","DOI":"10.1182\/blood.V93.7.2244"},{"key":"2020021219520746800_REF23","doi-asserted-by":"crossref","unstructured":"Rescigno M, Piguet V, Valzasina B, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction. A new role for fas ligand in inflammatory responses. J Exp Med.2000;192: 1661-1668.","DOI":"10.1084\/jem.192.11.1661"},{"key":"2020021219520746800_REF24","doi-asserted-by":"crossref","unstructured":"Schneider P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol.2000;322: 325-345.","DOI":"10.1016\/S0076-6879(00)22031-4"},{"key":"2020021219520746800_REF25","doi-asserted-by":"crossref","unstructured":"Genevee C, Diu A, Nierat J, Caignard A, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29\/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol.1992;22: 1261-1269.","DOI":"10.1002\/eji.1830220522"},{"key":"2020021219520746800_REF26","doi-asserted-by":"crossref","unstructured":"Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol.1992;22: 2573-2578.","DOI":"10.1002\/eji.1830221016"},{"key":"2020021219520746800_REF27","doi-asserted-by":"crossref","unstructured":"Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol.1992;22: 3191-3194.","DOI":"10.1002\/eji.1830221226"},{"key":"2020021219520746800_REF28","doi-asserted-by":"crossref","unstructured":"Hollenbaugh D, Grosmaire LS, Kullas CD, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J.1992;11: 4313-4321.","DOI":"10.1002\/j.1460-2075.1992.tb05530.x"},{"key":"2020021219520746800_REF29","doi-asserted-by":"crossref","unstructured":"Spriggs MK, Armitage RJ, Strockbine L, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med.1992;176: 1543-1550.","DOI":"10.1084\/jem.176.6.1543"},{"key":"2020021219520746800_REF30","unstructured":"Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol.1999;26: 276-289."},{"key":"2020021219520746800_REF31","doi-asserted-by":"crossref","unstructured":"Schanberg LE, Lee DM, Fleenor DE, et al. Characterization of human CD7 transgenic mice. J Immunol.1995;155: 2407-2418.","DOI":"10.4049\/jimmunol.155.5.2407"},{"key":"2020021219520746800_REF32","doi-asserted-by":"crossref","unstructured":"Nusslein HG, Frosch KH, Woith W, Lane P, Kalden JR, Manger B. Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. Eur J Immunol.1996;26: 846-850.","DOI":"10.1002\/eji.1830260418"},{"key":"2020021219520746800_REF33","doi-asserted-by":"crossref","unstructured":"Bigby M, Wang P, Fierro JF, Sy MS. Phorbol myristate acetate-induced down-modulation of CD4 is dependent on calmodulin and intracellular calcium. J Immunol.1990;144: 3111-3116.","DOI":"10.4049\/jimmunol.144.8.3111"},{"key":"2020021219520746800_REF34","doi-asserted-by":"crossref","unstructured":"Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol.2003;23: 1428-1440.","DOI":"10.1128\/MCB.23.4.1428-1440.2003"},{"key":"2020021219520746800_REF35","doi-asserted-by":"crossref","unstructured":"Ria F, Penna G, Adorini L. Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur J Immunol.1998;28: 2003-2016.","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<2003::AID-IMMU2003>3.0.CO;2-S"},{"key":"2020021219520746800_REF36","doi-asserted-by":"crossref","unstructured":"Hansen ER, Vejlsgaard GL, Cooper KD, et al. Leukemic T cells from patients with cutaneous T-cell lymphoma demonstrate enhanced activation through CDw60, CD2, and CD28 relative to activation through the T-cell antigen receptor complex. J Invest Dermatol.1993;100: 667-673.","DOI":"10.1111\/1523-1747.ep12472333"},{"key":"2020021219520746800_REF37","doi-asserted-by":"crossref","unstructured":"Fargnoli MC, Edelson RL, Berger CL, et al. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. Leukemia.1997;11: 1338-1346.","DOI":"10.1038\/sj.leu.2400745"},{"key":"2020021219520746800_REF38","doi-asserted-by":"crossref","unstructured":"Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature.1998;393: 480-483.","DOI":"10.1038\/31002"},{"key":"2020021219520746800_REF39","doi-asserted-by":"crossref","unstructured":"Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature.1998;393: 478-480.","DOI":"10.1038\/30996"},{"key":"2020021219520746800_REF40","doi-asserted-by":"crossref","unstructured":"Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature.1998;393: 474-478.","DOI":"10.1038\/30989"},{"key":"2020021219520746800_REF41","doi-asserted-by":"crossref","unstructured":"Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med.1999;5: 774-779.","DOI":"10.1038\/10495"},{"key":"2020021219520746800_REF42","doi-asserted-by":"crossref","unstructured":"Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med.1999;5: 780-787.","DOI":"10.1038\/10503"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/219\/1704993\/zh800105000219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/219\/1704993\/zh800105000219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:03:02Z","timestamp":1682748182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/1\/219\/20011\/Impaired-CD40L-signaling-is-a-cause-of-defective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1055","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}